Lo Andrew 4

What Happened

Andrew Lo, a director of BridgeBio Pharma, was granted restricted stock units (RSUs) on 2026-06-22. The filing shows two awards: 3,990 RSUs (reported as shares acquired at $0.00) and 5,277 RSUs reported as a derivative award—totaling 9,267 RSUs. The grants were reported on Form 4 filed 2026-06-24. No cash was paid for these awards (price $0.00; total reported value $0).

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely, within the typical 2-business-day window).
• Awards: 3,990 RSUs (direct) and 5,277 RSUs (derivative), total 9,267 RSUs. Price per unit: $0.00; reported value: $0.
• Vesting: Footnotes state the RSUs vest in full on 2027-06-22, contingent on continued service on the board (F1, F3).
• Each RSU equals a contingent right to one share of common stock (F2).
• Transaction code: A = award/grant.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

RSU grants are compensation awards that convert into actual shares only after vesting; they are not an immediate purchase or sale and thus don’t directly signal buying or selling activity. These RSUs will become common stock on the stated vesting date if the director remains in service. The filing contains no indication of a 10b5-1 plan, tax withholding on vesting, or that any shares were sold immediately.